Publication | Open Access
SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium
53
Citations
54
References
2022
Year
Unknown Venue
Inflammatory Lung DiseaseLung InflammationAdaptive Immune SystemImmunologyImmunodominanceImmunologic MechanismCd4 T Cell ResponsesImmune SystemCovid-19Human AirwaysSars-cov-2 Omicron VariantRespiratory InfectionImmunopathologySars-cov-2 OmicronRespiratory DiseasesImmune SurveillanceHumoral ImmunityT Cell ImmunityProtease UsageCell BiologyInfectious Respiratory DiseaseMedicineViral Immunity
Abstract In late 2021, the highly mutated SARS-CoV-2 Omicron variant emerged, raising concerns about its potential extensive immune evasion, increased transmissibility and pathogenicity. Here, we used organoids of the human airways and alveoli to investigate Omicron’s fitness and replicative potential in comparison with earlier SARS-CoV-2 variants. We report that Omicron replicates more rapidly in the airways and has an increased fitness compared to the early 614G variant and Delta. In contrast, Omicron did not replicate productively in human alveolar type 2 cells. Mechanistically, we show that Omicron does not efficiently use TMPRSS2 for entry or spread through cell-cell fusion. Altogether, our data show that Omicron has an altered tropism and protease usage, potentially explaining its higher transmissibility and decreased pathogenicity.
| Year | Citations | |
|---|---|---|
Page 1
Page 1